North Star Asset Management Inc. Grows Stake in Danaher Corporation $DHR

North Star Asset Management Inc. raised its stake in shares of Danaher Corporation (NYSE:DHR) by 3.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 117,564 shares of the conglomerate’s stock after purchasing an additional 4,158 shares during the period. North Star Asset Management Inc.’s holdings in Danaher were worth $23,224,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently modified their holdings of the company. Advisors Asset Management Inc. lifted its position in Danaher by 11.2% in the second quarter. Advisors Asset Management Inc. now owns 7,218 shares of the conglomerate’s stock worth $1,426,000 after buying an additional 725 shares during the last quarter. Laurel Wealth Advisors LLC increased its position in Danaher by 19,646.1% during the second quarter. Laurel Wealth Advisors LLC now owns 204,570 shares of the conglomerate’s stock valued at $40,411,000 after acquiring an additional 203,534 shares during the last quarter. South Plains Financial Inc. raised its stake in shares of Danaher by 30.8% in the second quarter. South Plains Financial Inc. now owns 1,109 shares of the conglomerate’s stock valued at $219,000 after acquiring an additional 261 shares during the period. CreativeOne Wealth LLC lifted its holdings in shares of Danaher by 38.6% in the 2nd quarter. CreativeOne Wealth LLC now owns 2,432 shares of the conglomerate’s stock worth $480,000 after acquiring an additional 677 shares during the last quarter. Finally, Weitz Investment Management Inc. boosted its stake in shares of Danaher by 6.1% during the 2nd quarter. Weitz Investment Management Inc. now owns 526,950 shares of the conglomerate’s stock worth $104,094,000 after purchasing an additional 30,300 shares during the period. Institutional investors own 79.05% of the company’s stock.

Insider Transactions at Danaher

In other news, SVP Georgeann Couchara sold 5,174 shares of the stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the transaction, the senior vice president directly owned 2,625 shares in the company, valued at approximately $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Teri List sold 3,298 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total transaction of $746,997.00. Following the completion of the transaction, the director directly owned 20,762 shares of the company’s stock, valued at $4,702,593. This trade represents a 13.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 30,248 shares of company stock valued at $6,609,663. Company insiders own 11.10% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Cowen reiterated a “buy” rating on shares of Danaher in a report on Wednesday, October 22nd. Bank of America dropped their price objective on Danaher from $230.00 to $220.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Danaher in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

Danaher Stock Down 0.2%

Shares of NYSE:DHR opened at $227.05 on Tuesday. The business’s 50 day moving average is $209.36 and its 200 day moving average is $202.34. The stock has a market cap of $160.38 billion, a P/E ratio of 46.81, a price-to-earnings-growth ratio of 3.28 and a beta of 0.81. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.71 EPS. Sell-side analysts predict that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. Danaher’s payout ratio is currently 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.